Merck (MRK) Amortizatization of Intangibles (2020 - 2026)
Merck (MRK) posted quarterly Amortizatization of Intangibles of $931.0 million for Q1 2026, up 55.95% YoY from $597.0 million in Q1 2025, and down 4.32% sequentially from $973.0 million in Q4 2025.
Merck (MRK) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Merck has disclosed Amortizatization of Intangibles across 7 years of filings, most recently posting $931.0 million for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 55.95% year-over-year to $931.0 million; the TTM figure through Mar 2026 stood at $3.1 billion (up 24.18% YoY), while the FY2025 annual figure was $2.8 billion, up 16.62% from the prior year.
- Amortizatization of Intangibles retreated to $931.0 million in Q1 2026, from $973.0 million in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for MRK reached as high as $973.0 million in Q4 2025 and fell as low as $460.0 million in Q3 2022.
- The 5-year median for Amortizatization of Intangibles is $597.0 million (2025), against an average of $602.8 million.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles declined 22.32% — and 2026, when it soared 55.95%.
- A 5-year view of Amortizatization of Intangibles shows it stood at $462.0 million in 2022, then changed by 0.0% to $462.0 million in 2023, then jumped by 46.1% to $675.0 million in 2024, then surged by 44.15% to $973.0 million in 2025, then decreased by 4.32% to $931.0 million in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $931.0 million, $973.0 million, and $623.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 1.70 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 107.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 931.00 Mn |
| Mar 31, 2026 | 931.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Dec 31, 2025 | 973.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Sep 30, 2025 | 623.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Jun 30, 2025 | 601.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Mar 31, 2025 | 597.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Dec 31, 2024 | 675.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Sep 30, 2024 | 633.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Jun 30, 2024 | 614.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Mar 31, 2024 | 473.00 Mn |
| Dec 31, 2023 | 462.00 Mn |
| Dec 31, 2023 | 462.00 Mn |